Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14355029 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2CA14CA12ALDH1A1CA1 | |
| SCHEMBL5511092 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2CA14CA12ALDH1A1CA1 | |
| SCHEMBL14752350 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2CA14CA12ALDH1A1CA1 | |
| SCHEMBL14668832 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12ALDH1A1CA1 | |
| SCHEMBL15034668 | 0.80 | CA1 (0.42) | SMN1; SMN2CA14CA12ALDH1A1CA1 | |
| SCHEMBL15034670 | 0.80 | CA1 (0.42) | SMN1; SMN2CA14CA12ALDH1A1CA1 | |
| SCHEMBL15034669 | 0.80 | CA1 (0.42) | SMN1; SMN2CA14CA12ALDH1A1CA1 | |
| SCHEMBL22667816 | 0.78 | SMN1; SMN2 (0.38) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL13575240 | 0.77 | CA1 (0.38) | SMN1; SMN2CA14CA12ALDH1A1CA1 | |
| SCHEMBL28583609 | 0.77 | CA1 (0.44) | SMN1; SMN2CA14CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109952360-A | Quantum dot dispersion liquid, self-luminous photosensitive polymer combination, the colour filter and image display device manufactured using it | 东友精细化工有限公司 | 2019-06-28 | — | — | CN | disclosed |
| CN-109810589-A | Light converts resin combination, light conversion layer folds substrate and image display device | 东友精细化工有限公司 | 2019-05-28 | — | — | CN | disclosed |
| US-8895497-B2 | Cathepsin S inhibitors | DCB-USA, LLC (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8778941-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20110166141-A1 | CATHEPSIN S INHIBITORS | DCB-USA, LLC (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166141-A1 | CATHEPSIN S INHIBITORS | DCB-USA, LLC (US) | 2011-07-07 | — | — | US | disclosed |
| EP-1603917-B1 | IMMUNOMODULATING HETEROCYCLIC COMPOUNDS | MEDIGENE LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7598247-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | SMN1; SMN2 837/4885CA14 2616/4885CA12 2722/4885 |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | SMN1; SMN2 837/4885CA14 2616/4885CA12 2722/4885 |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | SMN1; SMN2 4346/4885CA14 1816/4885CA12 1857/4885 |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | SMN1; SMN2 4346/4885CA14 1816/4885CA12 1857/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | SMN1; SMN2 4416/4885CA14 1516/4885CA12 1512/4885 |
| US-20110166141-A1 | CATHEPSIN S INHIBITORS | CTSS, CTSV, CTSB | SMN1; SMN2 4517/4885CA14 260/4885CA12 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.